Pulse Biosciences Stock Investor Sentiment

PLSE Stock  USD 19.34  0.02  0.10%   
About 61% of all Pulse Biosciences' shareholders are looking to take a long position. The analysis of overall sentiment of trading Pulse Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Pulse Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pulse Biosciences stock news signals to limit their universe of possible portfolio assets.
  

Pulse Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
58.4%
56.6%
57.8%
61.0%
55.7%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulse Biosciences Maximum Pain Price Across April 17th 2025 Option Contracts

Pulse Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Pulse Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Pulse Biosciences' options.
Calls PricePuts Price
over three months ago at simplywall.st         
Pulse Biosciences, Inc.s largest shareholder, Top Key Executive Robert Duggan sees holdings value fa...
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Pulse Biosciences Is In A Good Position To Deliver On Growth Plans
Yahoo News
over three months ago at finance.yahoo.com         
Acquisition by Mitchell Levinson of 322 shares of Pulse Biosciences at 10.0 subject to Rule 16b-3
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Zanganeh Mahkam of 200000 shares of Pulse Biosciences at 15.65 subject to Rule 16b-3
Macroaxis News
over three months ago at insidermonkey.com         
Pulse Biosciences, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three months ago at thelincolnianonline.com         
Pulse Biosciences Issues Quarterly Earnings Results
news
over three months ago at gurufocus.com         
Pulse Biosciences Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ...
Gurufocus Stories at Macroaxis
over three months ago at thelincolnianonline.com         
Pulse Biosciences Shares Cross Below Fifty Day Moving Average Heres Why
news
over three months ago at businesswire.com         
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
businesswire News
over three months ago at businesswire.com         
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
businesswire News
over three months ago at businesswire.com         
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 202...
businesswire News
over three months ago at businesswire.com         
Acquisition by Robert Duggan of 116656 shares of Pulse Biosciences at 9.54 subject to Rule 16b-3
businesswire News
over three months ago at thelincolnianonline.com         
Head to Head Review 3M and Pulse Biosciences
news
over three months ago at www.macroaxis.com         
Acquisition by Robert Duggan of 27000 shares of Pulse Biosciences at 10.38 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 161 shares by Mitchell Levinson of Pulse Biosciences at 11.0 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.

Pulse Biosciences Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.1512345678910111213Dec2025Feb 010203040
JavaScript chart by amCharts 3.21.15Pulse Biosciences Pulse Biosciences Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Acquisition by Robert Duggan of 6054 shares of Pulse Biosciences at 16.74 subject to Rule 16b-3
12/11/2024
2
Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3
12/13/2024
3
Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3
12/18/2024
4
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
01/03/2025
5
Acquisition by Paul LaViolette of 450000 shares of Pulse Biosciences at 18.43 subject to Rule 16b-3
01/08/2025
6
Pulse Biosciences Inc Appoints New CEO and Announces Strategic Developments
01/10/2025
7
Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
01/13/2025
8
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposiu...
01/21/2025
9
Acquisition by Zanganeh Mahkam of 30121 shares of Pulse Biosciences at 11.0 subject to Rule 16b-3
01/24/2025
10
Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
01/30/2025
11
Disposition of 30121 shares by Zanganeh Mahkam of Pulse Biosciences at 11.0 subject to Rule 16b-3
02/03/2025
12
Were Not Very Worried About Pulse Biosciences Cash Burn Rate
02/07/2025
13
Acquisition by Van Den Broek Richard of 20000 shares of Pulse Biosciences at 14.55 subject to Rule 16b-3
02/11/2025

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
News Freq…Investor S…